Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

14-11-2019

Saman Javed

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

Pavel Kapysh / Shutterstock.com

Seattle Genetics has asked the American Arbitration Association (AAA) to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.


Daiichi Sankyo, American Arbitration Association, Seattle Genetics, trastuzumab deruxtecan, breast cancer, antibody-drug conjugate

LSIPR